Medicine and Dentistry
Acute Leukemia
12%
Acute Promyelocytic Leukemia
12%
B Cell
50%
Beta1 Integrin
50%
Binding Affinity
25%
Bone Marrow Stromal Cell
20%
BRCA1
50%
BRCA2
50%
CD8 Antigen
38%
Cell Activation
50%
Cell Adhesion Molecule
29%
Cell Contact
29%
Cell Interaction
33%
Cell Line
25%
Chronic Myelogenous Leukemia
12%
Crizotinib
18%
Cytoreductive Surgery
35%
Debulking Surgery
25%
Endothelial Cell
50%
Endothelial Leukocyte Adhesion Molecule 1
12%
Epileptic Absence
12%
Erythroleukemia Cell
25%
Extracellular Matrix
12%
Fibronectin
33%
Fluorescence in Situ Hybridization
50%
Gene Expression
12%
Haematoxylin
12%
Hereditary Nonpolyposis Colorectal Cancer
50%
HL60
33%
Immunoglobulin A
16%
In Vitro
29%
Intercellular Adhesion Molecule 1
25%
K562 Cells
20%
Krukenberg Tumor
100%
Leukemia Cell Line
12%
Neoadjuvant Chemotherapy
25%
Neoplasm
96%
Non Small Cell Lung Cancer
50%
Ovarian Cancer
58%
Reverse Transcription Polymerase Chain Reaction
50%
Stroma
50%
Stromal Cell
100%
T Cell
16%
T Cell Subset
50%
Tumor Cell
50%
Tumor Necrosis Factor
12%
Vascular Cell Adhesion Molecule 1
54%
Very Late Activation Antigen 4
66%
Very Late Activation Antigen 5
54%
Visual Analog Scale
20%
Keyphrases
Adhesion
16%
Adhesion Molecules
29%
Advanced Non-small Cell Lung Carcinoma
18%
B Cells
50%
Binding Affinity
25%
Bone Marrow Stroma
50%
Cancer Vaccine
50%
CD4+
16%
Cell Contact
29%
Cell Interaction
33%
Cell Monolayer
33%
Cell Status
16%
Cell Trafficking
50%
Erythroleukemia Cells
25%
Extracellular Matrix
12%
Fibronectin
33%
First-in-human
50%
High-grade Serous Ovarian Cancer (HGSOC)
50%
High-risk Human Papillomavirus (HR-HPV)
50%
HL-60 Cells
33%
HPV16 E7
16%
Human Bone Marrow
100%
Human in Vitro Models
12%
Human Mesenchymal Stem Cells (hMSCs)
20%
Immunization
50%
Infectious Particles
16%
Inhibition Studies
20%
Integrin β1
50%
Interaction Pathway
12%
Intercellular Adhesion molecule-1 (ICAM-1)
12%
K562
37%
Laser Dissection Microscopy
50%
Leukemia Cell Lines
12%
Leukemic Cells
50%
Mediated Interaction
12%
Neoadjuvant Chemotherapy
25%
Phase I Clinical Trial
50%
Primary Debulking Surgery
16%
Promyelocytic Leukemia
12%
RNA Integrity
25%
RNA Replicon
50%
Semliki Forest Virus
16%
Stromal Cells
100%
Therapeutic Vaccine
16%
Tumor
16%
Tumor Cells
50%
Vascular Cell Adhesion molecule-1 (VCAM-1)
41%
VLA-4
66%
VLA-5
54%
Whole Section
25%
Immunology and Microbiology
Actin
8%
Alphavirus
16%
Beta1 Integrin
50%
Binding Affinity
25%
Cancer Vaccine
50%
CD29
8%
CD31
25%
CD44
12%
CD8
50%
Cell Activation
50%
Cell Adhesion Molecule
29%
Cell Contact
29%
Cell Interaction
33%
Cell Isolation
50%
Cell Line
37%
Cytotoxic T-Cell
50%
E-Selectin
25%
Epitope
8%
Erythroleukemia Cell
25%
Extracellular Matrix
12%
Fibroblast
8%
Fibronectin
33%
Gene Expression
25%
Human Papillomavirus Type 16
33%
Immune Response
33%
Immunocompetent Cell
16%
Intercellular Adhesion Molecule 1
37%
interferon
16%
Leukemia Cell Line
12%
Low Drug Dose
16%
Mouse
25%
Myeloid
12%
Replicon
50%
Reverse Transcription Polymerase Chain Reaction
50%
Semliki Forest Virus
33%
Smooth Muscle
8%
Stroma
50%
Survival Prediction
16%
T Cell Subset
50%
T-Helper Cell
33%
Tumor Cell
50%
Tumor Cell Line
8%
Tumor Necrosis Factor Alpha
25%
Vaccine Efficacy
50%
VCAM-1
66%
Very Late Activation Antigen 5
54%
VLA-4
66%
Wart Virus
50%
